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In light of the present opioid crisis, there is an urgent
need to identify novel, non-opioid drugs to treat
chronic pain. Drugs targeting 7-nicotinic
acetylcholine receptors (7 nAChRs) are of particular
interest. 7 nAChRs are expressed in different cells
within both the peripheral and central nervous
system, and in glial cells, including astrocytes and
microglia. Agonists with high selectivity for α7
nAChRs have demonstrated beneficial effects on
neuropsychiatric and neurological diseases by
decreasing neuroinflammation. However, little is
known about the beneficial effect of α7-selective
positive allosteric modulators (α7-PAMs) on these
diseases, including chronic pain. The overall objective
of this work is to evaluate 1) the anti-neuropathic
pain activities of PAM-2, a highly selective α7-PAM
(Arias et al., 2016) in a mouse model of drug-induced
neuropathic pain; and 2) the potentiating activity of
PAM-2 on (-)-nicotine-induced inhibition of
chemokine/cytokine release from human microglial
cells.
The anti-neuropathic pain activity of PAM-2 was tested
by using the oxaliplatin-induced neuropathic pain
animal model (Cavaletti et al., 2001). Mice (n =
10/condition) were intermittently administered (i.p.)
with 2.4 mg/kg oxaliplatin to develop neuropathic
pain. Mice were then administrated (p.o.) with vehicle,
1 or 3 mg/kg PAM-2, in an acute or sub-chronic (7 and
14 days) manner. The pain threshold was subsequently
determined by the cold plate test at 0, 15, 30, 45, and
60 min after treatment. Methyllycaconitine (MLA; 6
mg/kg), an α7-selective antagonist, was used to
determine receptor selectivity. Data were analyzed by
ANOVA, followed by Bonferroni’s pairwise
comparisons, and presented as mean ± SEM.
Cytokine/chemokine expression was induced in
human C20 microglial cells by exposing to interleukin-
1β (IL-1β; 20 ng/ml) for 18 h. Cells were stimulated
with IL-1β alone or in combination with PAM-2 (1-100
µM) and/or (-)-nicotine (3 µM). The levels of pro-
inflammatory chemokine/cytokines in the culture
media were measured by ELISA. These in vitro
experiments are preliminary, therefore, statistical
analyses have yet to be performed.
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1. PAM-2 inhibits neuropathic pain in mice
2. PAM-2 seems to potentiate IL-1β-induced 
chemokine/cytokine production in human 
microglial cells
3. PAM-2 seems to potentiate the inhibitory
effect of (-)-nicotine on IL-1β-induced 
CXCL10 production
4. PAM-2, and α7-PAMs in general, should 
be pursued as potential therapeutic 
agents to treat neuropathic pain 
PAM-2 inhibited neuropathic pain in mice
The anti-neuropathic activity elicited by PAM-2 
is mediated by 7 nAChRs
The anti-neuropathic activity elicited by PAM-2 
is increased after sub-chronic treatment
Fig. 1. Neuropathic pain was first induced with oxaliplatin. PAM-2 was then administrated
(p.o.), and the response to a thermal stimulus was subsequently evaluated by the cold plate
test. The licking latency was recorded at 0, 15, 30, 45, and 60 min after treatment.
Bonferroni’s tests indicated that PAM-2 at 3.0 mg/kg, but not 1.0 mg/kg, decreased
oxaliplatin-induced neuropathic pain (vs vehicle) during the 15-45 min period (P < 0.01).
Fig. 2. Neuropathic pain was first induced by oxaliplatin. MLA (6.0 mg/kg) was administered
(i.p.) 15 min before 3.0 mg/kg PAM-2 (p.o.), and the response to a thermal stimulus
subsequently evaluated by the cold plate test. The licking latency was recorded at 0, 15, 30,
45, and 60 min after treatment. Bonferroni’s tests indicated that MLA inhibited the anti-
neuropathic pain effect of PAM-2 during the 15-45 min period (P < 0.01), compared to PAM-2-
treated animals, whereas MLA did not change oxaliplatin-induced neuropathic pain.
Fig. 3. Mice were co-treated with 1.0 mg/kg PAM-2 (i.e., ineffective dose) and oxaliplatin for 7
and 14 days, and cold plate tests were performed 24 h after the last administration.
Bonferroni’s test indicated that PAM-2 decreased oxaliplatin-induced neuropathic pain after
14 days, but not after 7 days. **P < 0.01 vs vehicle; ^^P < 0.01 vs oxaliplatin).
0 20 40 60 80
0
5
10
15
20
25
Oxaliplatin
  PAM-2
(3 mg/kg)
PAM-2
(1 mg/kg)
Vehicle
Time after treatment (min)
L
ic
k
in
g
 l
a
te
n
c
y
 (
s
)
0 20 40 60 80
0
5
10
15
20
25
Time after treatment (min)
Oxaliplatin
PAM-2
PAM-2+MLA
MLA
Vehicle
L
ic
k
in
g
 l
a
te
n
c
y
 (
s
)
PAM-2 differentially modulated 
chemokine/cytokine production in human 
microglia
PAM-2
Fig. 4. Human C20 microglial cells were cultured (in 24-well plates) in the presence of
vehicle, PAM-2 (1-100 µM), IL-1β (20 ng/ml), IL-1β + PAM-2, IL-1β + nicotine (3 µM), or IL-
1β + nicotine + PAM-2, for 18 h. Chemokine/cytokine levels in the culture medium were
measured by ELISA.
1. Identify the molecular and cellular targets 
involved in the anti-neuropathic pain 
actions of PAM-2, and related compounds.
2. Further investigate the modulatory effects 
of PAM-2 on inflammatory signaling in 
astrocytes and microglia. 
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